Integra Lifesciences Holdings (IART) Non-Current Deferred Tax Liability (2009 - 2026)

Integra Lifesciences Holdings has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $3.5 million for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 94.22% year-over-year to $3.5 million; the TTM figure through Jun 2026 stood at $3.5 million (down 94.22% YoY), while the FY2025 annual figure was $5.7 million, down 97.85% from the prior year.
• Non-Current Deferred Tax Liability came in at $3.5 million for Q2 2026 at Integra Lifesciences Holdings, down from $6.1 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $263.4 million in Q4 2024 to a low of $3.5 million in Q2 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $81.7 million, with a median of $61.5 million recorded in 2022.
• The largest YoY upside for Non-Current Deferred Tax Liability was 83.2% in 2025 against a maximum downside of 97.85% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $218.3 million in 2022, then decreased by 0.87% to $216.4 million in 2023, then advanced by 21.72% to $263.4 million in 2024, then sank by 97.85% to $5.7 million in 2025, then tumbled by 38.74% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $3.5 million in Q2 2026, $6.1 million in Q1 2026, and $5.7 million in Q4 2025.